The Valence Group Advises Canexus on Its Sale to Chemtrade
The Valence Group has advised Canexus Corporation (TSX: CUS) on its sale to Chemtrade Logistics Income Fund (TSE: CHE.UN) for cash consideration of C$1.65 per common share, equivalent to an enterprise value of approximately C$900 million.
The transaction, which has been unanimously approved by the Canexus Board of Directors, is structured as a Plan of Arrangement and is subject to regulatory and shareholder approval, as well as other customary closing conditions. Canexus is recommending shareholders vote in favor of the transaction and closing is expected before the end of April 2017.
The Valence Group also provided a fairness opinion to the Board of Directors of Canexus.
Canexus produces sodium chlorate and chlor-alkali products largely for the pulp and paper and water treatment industries. Canexus' common shares (CUS) and debentures Series IV - CUS.DB.B; Series V - CUS.DB.C; Series VI - CUS.DB.D) trade on the Toronto Stock Exchange.
About The Valence Group
The Valence Group is a specialist investment bank offering M&A advisory services exclusively to companies and investors in the chemicals, materials and related sectors. The Valence Group team includes a unique combination of professionals with backgrounds in investment banking and strategy consulting within the chemicals and materials industries, all focused exclusively on providing M&A advisory services to the chemicals and materials sector. The firm’s offices are located in New York and London.
The Valence Group
Paul Lakind, 212-847-7339
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
SEOUL-SEMICONDUCTOR23.3.2018 19:30 | pressemeddelelse
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine
ELLIOTT-MANAGEMENT-CORP23.3.2018 17:07 | pressemeddelelse
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance
CO-CLOVIS-ONCOLOGY-INC23.3.2018 13:54 | pressemeddelelse
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe
CO-CLOVIS-ONCOLOGY-INC23.3.2018 13:52 | pressemeddelelse
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets
JANSSEN23.3.2018 13:48 | pressemeddelelse
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)
AITHEON23.3.2018 13:02 | pressemeddelelse
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum